Gut & Digestive

544 Papers, 30 Years, One Lab — The Healing Peptide with the Most Research and the Least Independent Evidence

Alpha-MSH's Anti-Inflammatory Fragment — And It May Work Completely Differently Than Everyone Thinks

Novo Nordisk's Long-Acting Amylin Analogue. The First New Mechanism in Obesity Pharmacology Since GLP-1. Phase 3 REDEFINE 1 (NEJM, June 2025): CagriSema = 22.7% Weight Loss — Among the Highest Ever Reported for Obesity Medication. Cagrilintide Monotherapy = 11.8% at 68 Weeks. Phase 3 Trials Completed. NDA Filing Expected Q1 2026. Not Yet Approved. Community Access Through Research Vendors.

The Original GHRP — Discovered 12 Years Before the Receptor It Activates Was Named. The Compound That Proved the Ghrelin System Existed Before Ghrelin Was Found. Why Every Subsequent GHRP Was Designed to Fix GHRP-6's Problems. The Hunger That Arrives in 20 Minutes. Cortisol and Prolactin: How Much, Why It Matters, When to Care. The Unexpected Cytoprotective Signal Via CD36. Why Some Bulkers Prefer It Over Ipamorelin on Purpose.

Scope appropriateness is the question: local gut peptides are being stacked for barrier integrity and inflammatory signaling, not for systemic regeneration claims.

Adds KPV’s local gut anti-inflammatory signal to the GLOW recovery-and-skin stack.

The Only Human Cathelicidin. Antimicrobial, Anti-Biofilm, Pro-Angiogenic, Immunomodulatory, Wound-Healing. Phase IIb Clinical Evidence in Chronic Wounds. Overexpressed in Rosacea, Ovarian Cancer, Breast Cancer, Lung Cancer, Melanoma. Tumor-Suppressive in Colon and Gastric Cancer. The Most Contextually Bidirectional Compound in this reference. Vitamin D Is Its Most Important Natural Inducer.

The World's First Approved Dual GCG/GLP-1 Receptor Agonist. NMPA-Approved in China June 2025 for Obesity. Second NMPA Approval September 2025 for T2D. Phase 3 T2D Data Published Back-to-Back in Nature December 2025. Originally Eli Lilly's LY3305677 — Licensed to Innovent Biologics for China Development. No FDA Submission as of Mid-2026. The Drug That Is Simultaneously Approved, Unavailable, and a Research Chemical Depending on Where You Are.

The TAME Trial: The First FDA-Recognized Study to Use 'Aging' as a Drug Indication. The Bannister Study: Diabetics on Metformin Outlive Non-Diabetics. The 2024 Cell Primate Paper: 6.1-Year Brain Aging Regression. The Exercise Controversy: Metformin Blunts the Mitochondrial Benefits of Training. B12 Depletion: The Most Important Long-Term Safety Issue. Metformin vs Rapamycin: The Same mTOR Pathway, Different Entry Points. Who Benefits Most. Who Shouldn't Use It.

The Drug That Was Going to Treat Leaky Gut and Celiac Disease — And How the Phase 3 Trial Ended. What Zonulin Actually Is and Why Tight Junction Regulation Is Hard to Measure. Four Phase 2 RCTs: Symptom Improvement With Gluten Challenge. The Phase 3 Discontinuation in 2022. The N-Acetyl Modification That Limitless Sells: What It Adds and What It Doesn’t Change. How This Differs From BPC-157 and KPV in the Gut Stack.

FDA-Approved at 50 mg for Opioid and Alcohol Use Disorder Since 1984. Off-Label at 1.5-4.5 mg (LDN) — Two Completely Different Mechanisms at Two Completely Different Doses. TLR4 Blockade on Microglia. The Endorphin Rebound. A Lancet Rheumatology RCT in 2024. An Evidence Base Growing Faster Than Pharma Has Any Reason to Fund. The Most Favorably Tolerated Prescription Drug in Its Evidence Literature.

The First True Oral GLP-1: Take It Anytime, With or Without Food, No Injection. ATTAIN-1 (NEJM 2025; n=3,127; 72 Weeks): -11.2% Body Weight at 36mg. Why Small Molecule Matters: The Chemistry That Makes This Pill Possible When No Peptide Could Be. Orforglipron vs Oral Semaglutide vs Injectable GLP-1s: The Efficacy-Accessibility Trade-Off. ATTAIN-MAINTAIN: It Maintains Weight Loss After Switching Off Wegovy and Zepbound. Why This Compound Changes Who Gets GLP-1 Therapy.

28.7% Weight Loss in Phase 3. The Most Effective Weight Loss Drug Ever Trialed. Not Approved. Not Available by Prescription. The Community Is Already Using It. And It Is Not the Same Drug as Tirzepatide.

The Glucagon Rehabilitation Story. Phase 2 MASH (NEJM July 2024): 62% MASH Resolution vs 14% Placebo. Phase 3 SYNCHRONIZE-1 (April 2026): -16.6% Weight Loss at 76 Weeks. FDA Breakthrough Therapy for MASH September 2024. LIVERAGE Phase 3 MASH Ongoing. Why Glucagon in Metabolic Disease? The GLP-1 + GCGR Advantage Over GLP-1 + GIPR for Liver Disease. The Most Important Obesity Drug for MASH Patients That Nobody in the Community Has Heard Of.

The Most Physiologically Broad Compound in this reference. 28 Amino Acids. Every System in the Body. VPAC1 and VPAC2. The 90-Second Half-Life Problem That Blocked IV Use. How Intranasal Administration Changed Everything. Dr. Shoemaker's CIRS Protocol: 300+ Physicians, 90%+ Symptom Reduction. The Long-COVID Connection. Aviptadil COVID ARDS Trials. The Mast Cell / MCAS Intersection. Why the Community Uses It and What the Evidence Actually Shows.

Most Widely Used Peptide Healing Combination in Community History